| Product Code: ETC13378739 | Publication Date: Apr 2025 | Updated Date: Aug 2026 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sachin Kumar Rai | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
| Market Size (2025) | USD 650 Billion |
| Forecast Size (2032) | USD 930 Billion |
| CAGR | 5.2% |
| Base Year | 2025 |
| Forecast Period | 2026-2032 |
| Largest Region | Asia |
| Fastest Growing Region | Africa |
| Largest Segment | Inactivated Vaccine |
| Fastest Growing Segment | Conjugate Vaccine |
| Leading Companies | Sanofi Pasteur, GlaxoSmithKline, Bharat Biotech, Pfizer, Merck |

The Global Typhoid Fever Vaccine Market was estimated at USD 650 Billion in 2025 and is projected to reach USD 930 Billion by 2032, growing at a CAGR of 5.2% from 2026 to 2032.
The Global Typhoid Fever Vaccine Market is undergoing substantial transformations influenced by the heightened emphasis placed on preventive healthcare measures. Key players are investing in innovative vaccine formulations, driven by the significant incidence of typhoid fever in developing nations. Additionally, an enhanced public health focus is reshaping healthcare infrastructure, fostering a more conducive environment for vaccine distribution and administration.
One of the market's distinctive characteristics is the shift from traditional vaccines to advanced options, such as conjugate vaccines. As nations strive to eliminate typhoid entirely, partnerships between government entities and pharmaceutical companies are pivotal in promoting widespread vaccination programs. The interplay of these factors underscores the market's critical influence on overall public health initiatives.
This graph illustrates the annual growth rates of the Global Typhoid Fever Vaccine Market from 2022 to 2032, highlighting a steady upward trajectory and projected expansion over the forecast period.

The table below presents the year‑wise growth rates along with the key drivers influencing the market
| Year | Growth Rate (%) | Major Drivers |
| 2022 | 3.82 | Supply chain uncertainties contributed to fluctuating typhoid vaccine availability for healthcare providers. |
| 2023 | 8.03 | Changing competitive dynamics among manufacturers enhances the accessibility of typhoid vaccines. |
| 2024 | 3.07 | Increased regulatory scrutiny ensures higher compliance with typhoid vaccine safety standards. |
| 2025 | 4.48 | Healthcare companies are prioritizing skilled personnel to improve typhoid vaccine distribution efficiency. |
| 2026 | 6.49 | Manufacturers actively pursue eco-friendly processes, driving the sustainable production of typhoid vaccines. |
| 2027 | 1.01 | A shift toward preventive healthcare encourages higher community engagement in typhoid vaccination campaigns. |
| 2028 | 7.93 | Telehealth platforms are facilitating remote consultations, promoting wider acceptance of typhoid vaccinations. |
| 2029 | 5.84 | Public health organizations are facing rising costs for raw materials affecting typhoid vaccine pricing. |
| 2030 | 4.31 | As emerging markets expand, the demand for typhoid vaccines is expected to surge significantly. |
| 2031 | 5.31 | Innovative drug delivery systems are enhancing the effectiveness of typhoid vaccines in various demographics. |
| 2032 | 6.01 | In the Asia-Pacific region, strategic investments in vaccine production are driving typhoid vaccine growth. |
Note - Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary research methodology, combining internal industry data, secondary research, and primary validation, updated periodically to reflect current market conditions. As markets evolve rapidly, figures for certain industries may vary slightly and are intended as informed estimates rather than absolute figures. For the most current market sizing, we recommend validating figures with a 6Wresearch analyst.
Below are some of the specific key takeaways from the market, including:
Despite the growth momentum, the Global Typhoid Fever Vaccine Market faces substantial challenges, notably in regions with limited healthcare infrastructure. For instance, it is estimated that over 30% of the population in low-income countries lacks access to basic vaccination services. Moreover, cold chain logistics, which are essential for maintaining vaccine efficacy, can impose additional operational costs, often exceeding $200,000 for distribution in remote areas. For example, organizations like Médecins Sans Frontières have reported difficulties in ensuring vital vaccines reach targeted populations due to infrastructural limitations and high logistical costs.
Three distinct trends shape the Global Typhoid Fever Vaccine Market currently. The first is the shift towards conjugate vaccines, particularly as research indicates they offer lasting immunity compared to traditional vaccines. GlaxoSmithKline has reported promising efficacy rates for their new conjugate vaccine released in 2021, highlighting a significant departure from prior offerings. A second trend is the increasing integration of digital platforms for vaccination tracking and outreach, particularly in regions experiencing outbreaks. For instance, a pilot project in India began in 2022 aimed at using a mobile app to enhance public engagement and vaccination compliance. Additionally, public-private partnerships are becoming more prevalent; Sanofi's collaboration with various health ministries enhances distribution channels and education on typhoid prevention.
Several opportunities are emerging within the Global Typhoid Fever Vaccine Market. Investments in local manufacturing capabilities represent a critical avenue for growth, especially in Africa and Asia. For example, Bharat Biotech announced plans in 2023 to establish a manufacturing facility in Nigeria, expected to produce over 15 million doses annually. Furthermore, the push for innovative delivery methods, such as needle-free injections, is gaining traction; this technology could enhance vaccination rates post-2025. Government-led initiatives, particularly for global health funding, aim to incentivize vaccine production and distribution in underserved areas. This strategy reflects an anticipated increase in funding allocations, potentially exceeding $5 billion in the next five years.
In the Global Typhoid Fever Vaccine Market, the Inactivated Vaccine segment leads with an estimated ~45% share in 2025. This prominence is attributed to its established efficacy and the widespread acceptance among healthcare professionals. Conversely, the Conjugate Vaccine segment is recognized as the fastest-growing, projected to witness a CAGR of 8.5% from 2026 to 2032. The growing preferences for conjugate vaccines stem from their ability to provide longer-lasting immunity, aligning with public health goals to eliminate typhoid fever in endemic regions.
Among various technologies utilized in vaccine production, the Injectable Vaccine segment commands a notable share, estimated at ~60% in 2025. Its widespread acceptance in medical practices solidifies its leadership. On the other hand, the Oral Vaccine segment is the fastest growing, expected to achieve a CAGR of 7.2% from 2026 to 2032. The demand for oral vaccines arises from their ease of administration and reduction of needle-related complications, thereby catering to a broader demographic.
The Hospitals route of administration leads the Global Typhoid Fever Vaccine Market, with an approximate ~50% share in 2025, owing to their established systems and access to medical professionals. In contrast, Government Programs are anticipated to be the fastest growing, expected to see a CAGR of 6.8% from 2026 to 2032. Government initiatives are increasingly incorporating vaccination programs, reflecting a strategic focus on public health and the control of typhoid fever.
Within the Global Typhoid Fever Vaccine Market, Pediatric Patients constitute the largest end-use segment, representing ~40% of the market share in 2025 due to targeted vaccination campaigns in younger demographics. Meanwhile, the Travelers segment is expected to experience the fastest growth, with a projected CAGR of 9.3% from 2026 to 2032. The rise in global travel and heightened awareness of typhoid risk among tourists spur this increasing demand.
Asia dominates the Global Typhoid Fever Vaccine Market, commanding ~50% market share in 2025. This is primarily due to the high incidence rate of typhoid and investments in healthcare infrastructure. Africa is recognized as the fastest-growing region, projected to see a CAGR of 6.7% from 2026 to 2032. The growing recognition of typhoid prevention and government support for vaccination initiatives contribute to the region's rapid expansion.
The regulatory landscape surrounding the Global Typhoid Fever Vaccine Market is marked by several key initiatives aimed at eradicating the disease and promoting vaccination. Strong governmental commitment plays a crucial role in driving market developments, facilitating access and innovation in vaccine distribution.
The trajectory of the Global Typhoid Fever Vaccine Market is likely to pivot toward integrating advanced technologies such as mRNA-based vaccines, reflecting the growing inclination for rapid response mechanisms within vaccine development. Recent evidence from GlaxoSmithKline's R&D initiatives indicates an emphasis on faster production timelines and improving vaccine efficacy rates. As countries enhance their healthcare frameworks, investments in local manufacturing facilities, particularly in Africa and Asia, will galvanize efforts to achieve widespread vaccination coverage while ensuring adaptability to emerging strains of the disease.
Recent advancements in the Global Typhoid Fever Vaccine Market showcase the proactive measures undertaken by key players aimed at enhancing vaccine accessibility and efficacy. The developments are indicative of a market that is adapting to the urgent need for improved healthcare solutions.
The Global Typhoid Fever Vaccine Market exhibits a consolidated structure, wherein a handful of leading companies significantly influence market trends and dynamics. These players leverage extensive research capabilities and established distribution networks to dominate their respective segments. Their competitive advantages evolve from strong R&D investments, partnerships with government entities, and strategic maneuvering to expand their global footprint.
| Leading Company | Core Strength | Strategic Focus |
|---|---|---|
| Sanofi Pasteur | Strong governmental partnerships for broader vaccine access | Expanding distribution networks in underserved regions |
| GlaxoSmithKline | Innovative research capabilities in vaccine development | Increasing public awareness and prevention strategies |
| Bharat Biotech | Local manufacturing proficiency with cost-effective solutions | Enhancing regional production capacities in Africa and Asia |
| Pfizer | Expertise in immunotherapy and vaccine integrations | Focus on innovative delivery methods and logistics |
| Merck | Robust pipeline for advanced vaccine technologies | Commitment to hybrid vaccine strategies addressing multiple strains |
The competitive landscape indicates a clear push towards partnerships and technological advancements that are set to redefine vaccine distribution and efficiency, enhancing public health outcomes globally.
Global Typhoid Fever Vaccine Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Typhoid Fever Vaccine Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Typhoid Fever Vaccine Market Revenues & Volume, 2022 & 2032F |
3.3 Global Typhoid Fever Vaccine Market - Industry Life Cycle |
3.4 Global Typhoid Fever Vaccine Market - Porter's Five Forces |
3.5 Global Typhoid Fever Vaccine Market Revenues & Volume Share, By Regions, 2022 & 2032F |
3.6 Global Typhoid Fever Vaccine Market Revenues & Volume Share, By Type, 2022 & 2032F |
3.7 Global Typhoid Fever Vaccine Market Revenues & Volume Share, By Vaccine Technology, 2022 & 2032F |
3.8 Global Typhoid Fever Vaccine Market Revenues & Volume Share, By Route of Administration, 2022 & 2032F |
3.9 Global Typhoid Fever Vaccine Market Revenues & Volume Share, By End Use, 2022 & 2032F |
4 Global Typhoid Fever Vaccine Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Typhoid Fever Vaccine Market Trends |
6 Global Typhoid Fever Vaccine Market, 2022-2032 |
6.1 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Type, 2022-2032 |
6.1.1 Overview & Analysis |
6.1.2 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Live-Attenuated, 2022-2032 |
6.1.3 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Inactivated, 2022-2032 |
6.1.4 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Conjugate Vaccine, 2022-2032 |
6.1.5 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Recombinant Vaccine, 2022-2032 |
6.2 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Vaccine Technology, 2022-2032 |
6.2.1 Overview & Analysis |
6.2.2 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Oral Vaccine, 2022-2032 |
6.2.3 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Injectable Vaccine, 2022-2032 |
6.2.4 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Polysaccharide-Based, 2022-2032 |
6.2.5 Global Typhoid Fever Vaccine Market, Revenues & Volume, By DNA-Based, 2022-2032 |
6.3 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Route of Administration, 2022-2032 |
6.3.1 Overview & Analysis |
6.3.2 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Hospitals, 2022-2032 |
6.3.3 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Clinics, 2022-2032 |
6.3.4 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Pharmacies, 2022-2032 |
6.3.5 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Government Programs, 2022-2032 |
6.4 Global Typhoid Fever Vaccine Market, Revenues & Volume, By End Use, 2022-2032 |
6.4.1 Overview & Analysis |
6.4.2 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Pediatric Patients, 2022-2032 |
6.4.3 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Travelers, 2022-2032 |
6.4.4 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Endemic Regions, 2022-2032 |
6.4.5 Global Typhoid Fever Vaccine Market, Revenues & Volume, By Military Personnel, 2022-2032 |
7 North America Typhoid Fever Vaccine Market, Overview & Analysis |
7.1 North America Typhoid Fever Vaccine Market Revenues & Volume, 2022-2032 |
7.2 North America Typhoid Fever Vaccine Market, Revenues & Volume, By Countries, 2022-2032 |
7.2.1 United States (US) Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
7.2.2 Canada Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
7.2.3 Rest of North America Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
7.3 North America Typhoid Fever Vaccine Market, Revenues & Volume, By Type, 2022-2032 |
7.4 North America Typhoid Fever Vaccine Market, Revenues & Volume, By Vaccine Technology, 2022-2032 |
7.5 North America Typhoid Fever Vaccine Market, Revenues & Volume, By Route of Administration, 2022-2032 |
7.6 North America Typhoid Fever Vaccine Market, Revenues & Volume, By End Use, 2022-2032 |
8 Latin America (LATAM) Typhoid Fever Vaccine Market, Overview & Analysis |
8.1 Latin America (LATAM) Typhoid Fever Vaccine Market Revenues & Volume, 2022-2032 |
8.2 Latin America (LATAM) Typhoid Fever Vaccine Market, Revenues & Volume, By Countries, 2022-2032 |
8.2.1 Brazil Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
8.2.2 Mexico Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
8.2.3 Argentina Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
8.2.4 Rest of LATAM Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
8.3 Latin America (LATAM) Typhoid Fever Vaccine Market, Revenues & Volume, By Type, 2022-2032 |
8.4 Latin America (LATAM) Typhoid Fever Vaccine Market, Revenues & Volume, By Vaccine Technology, 2022-2032 |
8.5 Latin America (LATAM) Typhoid Fever Vaccine Market, Revenues & Volume, By Route of Administration, 2022-2032 |
8.6 Latin America (LATAM) Typhoid Fever Vaccine Market, Revenues & Volume, By End Use, 2022-2032 |
9 Asia Typhoid Fever Vaccine Market, Overview & Analysis |
9.1 Asia Typhoid Fever Vaccine Market Revenues & Volume, 2022-2032 |
9.2 Asia Typhoid Fever Vaccine Market, Revenues & Volume, By Countries, 2022-2032 |
9.2.1 India Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
9.2.2 China Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
9.2.3 Japan Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
9.2.4 Rest of Asia Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
9.3 Asia Typhoid Fever Vaccine Market, Revenues & Volume, By Type, 2022-2032 |
9.4 Asia Typhoid Fever Vaccine Market, Revenues & Volume, By Vaccine Technology, 2022-2032 |
9.5 Asia Typhoid Fever Vaccine Market, Revenues & Volume, By Route of Administration, 2022-2032 |
9.6 Asia Typhoid Fever Vaccine Market, Revenues & Volume, By End Use, 2022-2032 |
10 Africa Typhoid Fever Vaccine Market, Overview & Analysis |
10.1 Africa Typhoid Fever Vaccine Market Revenues & Volume, 2022-2032 |
10.2 Africa Typhoid Fever Vaccine Market, Revenues & Volume, By Countries, 2022-2032 |
10.2.1 South Africa Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
10.2.2 Egypt Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
10.2.3 Nigeria Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
10.2.4 Rest of Africa Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
10.3 Africa Typhoid Fever Vaccine Market, Revenues & Volume, By Type, 2022-2032 |
10.4 Africa Typhoid Fever Vaccine Market, Revenues & Volume, By Vaccine Technology, 2022-2032 |
10.5 Africa Typhoid Fever Vaccine Market, Revenues & Volume, By Route of Administration, 2022-2032 |
10.6 Africa Typhoid Fever Vaccine Market, Revenues & Volume, By End Use, 2022-2032 |
11 Europe Typhoid Fever Vaccine Market, Overview & Analysis |
11.1 Europe Typhoid Fever Vaccine Market Revenues & Volume, 2022-2032 |
11.2 Europe Typhoid Fever Vaccine Market, Revenues & Volume, By Countries, 2022-2032 |
11.2.1 United Kingdom Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
11.2.2 Germany Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
11.2.3 France Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
11.2.4 Rest of Europe Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
11.3 Europe Typhoid Fever Vaccine Market, Revenues & Volume, By Type, 2022-2032 |
11.4 Europe Typhoid Fever Vaccine Market, Revenues & Volume, By Vaccine Technology, 2022-2032 |
11.5 Europe Typhoid Fever Vaccine Market, Revenues & Volume, By Route of Administration, 2022-2032 |
11.6 Europe Typhoid Fever Vaccine Market, Revenues & Volume, By End Use, 2022-2032 |
12 Middle East Typhoid Fever Vaccine Market, Overview & Analysis |
12.1 Middle East Typhoid Fever Vaccine Market Revenues & Volume, 2022-2032 |
12.2 Middle East Typhoid Fever Vaccine Market, Revenues & Volume, By Countries, 2022-2032 |
12.2.1 Saudi Arabia Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
12.2.2 UAE Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
12.2.3 Turkey Typhoid Fever Vaccine Market, Revenues & Volume, 2022-2032 |
12.3 Middle East Typhoid Fever Vaccine Market, Revenues & Volume, By Type, 2022-2032 |
12.4 Middle East Typhoid Fever Vaccine Market, Revenues & Volume, By Vaccine Technology, 2022-2032 |
12.5 Middle East Typhoid Fever Vaccine Market, Revenues & Volume, By Route of Administration, 2022-2032 |
12.6 Middle East Typhoid Fever Vaccine Market, Revenues & Volume, By End Use, 2022-2032 |
13 Global Typhoid Fever Vaccine Market Key Performance Indicators |
14 Global Typhoid Fever Vaccine Market - Export/Import By Countries Assessment |
15 Global Typhoid Fever Vaccine Market - Opportunity Assessment |
15.1 Global Typhoid Fever Vaccine Market Opportunity Assessment, By Countries, 2022 & 2032F |
15.2 Global Typhoid Fever Vaccine Market Opportunity Assessment, By Type, 2022 & 2032F |
15.3 Global Typhoid Fever Vaccine Market Opportunity Assessment, By Vaccine Technology, 2022 & 2032F |
15.4 Global Typhoid Fever Vaccine Market Opportunity Assessment, By Route of Administration, 2022 & 2032F |
15.5 Global Typhoid Fever Vaccine Market Opportunity Assessment, By End Use, 2022 & 2032F |
16 Global Typhoid Fever Vaccine Market - Competitive Landscape |
16.1 Global Typhoid Fever Vaccine Market Revenue Share, By Companies, 2025 |
16.2 Global Typhoid Fever Vaccine Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here